Skip to main content
AngioLab, Inc. logo

AngioLab, Inc. — Investor Relations & Filings

Ticker · 251280 ISIN · KR7251280004 KO Professional, scientific and technical activities
Open in API
Filings indexed 173 across all filing types
Latest filing 2020-12-01 Regulatory Filings
Country KR South Korea
Listing KO 251280

About AngioLab, Inc.

https://angiolab.co.kr/

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Recent filings

Filing Released Lang Actions
지정자문인선임계약의체결
Regulatory Filings Classification · 1% confidence The document is a short, structured announcement regarding the appointment of a new designated advisor (Daishin Securities) following the termination of a previous contract. It does not constitute a full financial report or a specific regulatory filing category like M&A or dividends. As it is a corporate announcement regarding a specific operational change that does not fit into the other specialized categories, it is best classified as a general regulatory filing.
2020-12-01 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 1% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) meeting held by AngioLab. It provides logistical details such as the date, time, location, attendees, and agenda, and confirms that the IR materials were posted to the Korea Exchange's disclosure system. Since it is a brief announcement regarding the occurrence of an event and the availability of materials rather than the presentation deck itself, it falls under the category of a regulatory filing announcement.
2020-10-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) meeting (기업설명회). It provides the date, time, location, purpose, and target audience for the event. Since it is an announcement of an upcoming presentation rather than the presentation slides themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2020-10-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a reduction in stake) by a major shareholder (Company K Partners). This type of filing is used to notify the market when a shareholder crosses a significant ownership threshold or changes their holdings, which corresponds to the 'Major Shareholding Notification' category.
2020-10-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document tracks changes in share ownership (5% rule) by a major shareholder (KB Investment). It is not an announcement of a report, but the report itself, detailing specific transaction dates, share counts, and the nature of the holdings. Therefore, it falls under the 'Major Shareholding Notification' category.
2020-09-24 Korean
기타주요경영사항(자율공시)(스팩합병 철회)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from AngioLab regarding the withdrawal of a preliminary listing application for the KOSDAQ market. It is a short, formal disclosure of a corporate event (withdrawal of a merger/listing process) rather than a full financial report or a specific category like M&A or Share Issue. Since it does not fit into the specific categories for M&A (which usually implies an active deal) or other specialized categories, it falls under the general regulatory filing category.
2020-09-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.